LOW-DOSE RECOMBINANT-HUMAN-ERYTHROPOIETIN THERAPY IN CHRONIC-HEMODIALYSIS PATIENTS

被引:17
作者
DUFF, DR [1 ]
GOLPER, TA [1 ]
SLOAN, RS [1 ]
BRIER, ME [1 ]
ARONOFF, GR [1 ]
机构
[1] UNIV LOUISVILLE, SCH MED, DEPT PHARMACOL, LOUISVILLE, KY 40292 USA
关键词
HEMODIALYSIS; ERYTHROPOIETIN; END-STAGE RENAL DISEASE; ANEMIA; VASCULAR ACCESS; TRANSFUSIONS; HYPERTENSION;
D O I
10.1016/S0272-6386(12)80291-5
中图分类号
R5 [内科学]; R69 [泌尿科学(泌尿生殖系疾病)];
学科分类号
1002 ; 100201 ;
摘要
To test the hypothesis that low-dose recombinant human erythropoietin (r-HuEpo) would be effective and safe therapy for the anemia of end-stage renal failure, we studied 37 chronic hemodialysis patients for 3 months before and 6 months after beginning treatment with r-HuEpo, 3,000 U, administered initially intravenously (IV) three times weekly. Hematocrit increased from a mean of 25.2 vol% into the target range (mean, 32.2 vol%, a 28% increase) by 4 months. Transfusion requirements were dramatically reduced. Eight patients (22%) had exacerbated or new development of hypertension, while in trials using higher doses this occurred in 35%. Vascular access thrombosis, dialyzer clotting, and seizures were not seen more frequently during r-HuEpo therapy. Dialyzer reuse was not affected. Low-dose r-HuEpo therapy is effective in most hemodialysis patients and may be associated with less adverse effects because of the slower increase in blood viscosity. As targets are reached, downward dosage adjustments need to be smaller when using an initial low-dose regimen. © 1991, National Kidney Foundation, Inc.. All rights reserved.
引用
收藏
页码:60 / 64
页数:5
相关论文
共 10 条
  • [1] BOMMER J, 1987, Nephrology Dialysis Transplantation, V2, P238
  • [2] Bommer J, 1988, Contrib Nephrol, V66, P85
  • [3] RECOMBINANT HUMAN ERYTHROPOIETIN - 18 MONTHS EXPERIENCE IN HEMODIALYSIS-PATIENTS
    CANAUD, B
    POLITOBOULOUX, C
    GARRED, LJ
    RIVORY, JP
    DONNADIEU, P
    TAIB, J
    FLORENCE, P
    MION, C
    [J]. AMERICAN JOURNAL OF KIDNEY DISEASES, 1990, 15 (02) : 169 - 175
  • [4] CORRECTION OF THE ANEMIA OF END-STAGE RENAL-DISEASE WITH RECOMBINANT-HUMAN-ERYTHROPOIETIN - RESULTS OF A COMBINED PHASE-I AND PHASE-II CLINICAL-TRIAL
    ESCHBACH, JW
    EGRIE, JC
    DOWNING, MR
    BROWNE, JK
    ADAMSON, JW
    [J]. NEW ENGLAND JOURNAL OF MEDICINE, 1987, 316 (02) : 73 - 78
  • [5] RECOMBINANT HUMAN ERYTHROPOIETIN IN ANEMIC PATIENTS WITH END-STAGE RENAL-DISEASE - RESULTS OF A PHASE-III MULTICENTER CLINICAL-TRIAL
    ESCHBACH, JW
    ABDULHADI, MH
    BROWNE, JK
    DELANO, BG
    DOWNING, MR
    EGRIE, JC
    EVANS, RW
    FRIEDMAN, EA
    GRABER, SE
    HALEY, NR
    KORBET, S
    KRANTZ, SB
    LUNDIN, AP
    NISSENSON, AR
    OGDEN, DA
    PAGANINI, EP
    RADER, B
    RUTSKY, EA
    STIVELMAN, J
    STONE, WJ
    TESCHAN, P
    VANSTONE, JC
    VANWYCK, DB
    ZUCKERMAN, K
    ADAMSON, JW
    [J]. ANNALS OF INTERNAL MEDICINE, 1989, 111 (12) : 992 - 1000
  • [6] Kuhn K, 1988, Contrib Nephrol, V66, P94
  • [7] HEMODYNAMICS OF UREMIC ANEMIA
    NEFF, MS
    KIM, KE
    PERSOFF, M
    ONESTI, G
    SWARTZ, C
    [J]. CIRCULATION, 1971, 43 (06) : 876 - &
  • [8] BLOOD RHEOLOGY AND HYPERTENSION IN HEMODIALYSIS-PATIENTS TREATED WITH ERYTHROPOIETIN
    SCHAEFER, RM
    LESCHKE, M
    STRAUER, BE
    HEIDLAND, A
    [J]. AMERICAN JOURNAL OF NEPHROLOGY, 1988, 8 (06) : 449 - 453
  • [9] IRON STATUS IN PATIENTS RECEIVING ERYTHROPOIETIN FOR DIALYSIS-ASSOCIATED ANEMIA
    VANWYCK, DB
    STIVELMAN, JC
    RUIZ, J
    KIRLIN, LF
    KATZ, MA
    OGDEN, DA
    [J]. KIDNEY INTERNATIONAL, 1989, 35 (02) : 712 - 716
  • [10] EFFECT OF HUMAN ERYTHROPOIETIN DERIVED FROM RECOMBINANT-DNA ON THE ANEMIA OF PATIENTS MAINTAINED BY CHRONIC-HEMODIALYSIS
    WINEARLS, CG
    PIPPARD, MJ
    DOWNING, MR
    OLIVER, DO
    REID, C
    COTES, PM
    [J]. LANCET, 1986, 2 (8517) : 1175 - 1178